A 36-month, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment (MCI).

Trial Profile

A 36-month, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment (MCI).

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Ladostigil (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Avraham Pharmaceuticals
  • Most Recent Events

    • 14 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 19 Sep 2016 This trial was completed in Germany (end date: 26-07-2016), according to European Clinical Trials Database.
    • 27 Aug 2016 This trial was completed in Austria (End Date: 26 Jul 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top